VTVT vTv Therapeutics Inc.: Price-to-Projected Revenue Ratio

vTv Therapeutics - graphic logo of issuer VTVT

The development of TTP399 with FDA support and streamlined international drug distribution logistics ensure high margins for vTv Therapeutics Inc. (VTVT). The GURU.Markets service provides this chart, where the company's modeled P/S reaches a value of 1.90, capturing market expectations. The current strategy is based on scaling clinical trials of the innovative molecule for a subsequent global market entry into diabetes therapy.

vTv Therapeutics, Inc. - VTVT Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for vTv Therapeutics Inc (VTVT)

- market price and analyst price targets:
Summary company analytics:vTv Therapeutics Inc (VTVT)
Original product of vTv Therapeutics, Inc.

Forward P/S determines the market value of a business relative to expected revenue, allowing for the identification of an undervalued asset or the risk of a "value trap." By analyzing the forward P/S of vTv Therapeutics Inc. (VTVT), an investor assesses the capitalization rate of projected sales, which is critical for vTv Therapeutics Inc. (VTVT) due to its dependence on clinical trial outcomes and the difficulty of raising capital amid low cash flow predictability.

Competing companies

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple soleno.life SLNO|Forward P/S Multiple FOLD (amicusrx.com)|Market Cap to Expected Sales Ratio 89bio (ETNB)|Agios - Forward P/S Multiple|Structure Corp - Price to Expected Revenue Ratio|mimedx.com (MDXG) - Price-to-Projected Revenue Ratio|Future Price to Revenue RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune Pharma (ALT)|Price-to-Projected Revenue Ratio AARD (Aardvark Therapeutics Corp)|Forward P/S Multiple SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Market Cap to Future Revenue Ratio|BMEA: Forward Price-to-Revenue Multiple|Forward Price to Sales QNCX (Quince Therapeutics Inc)|GUTS (Fractyl) - Forward Price-to-Revenue Multiple|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio